Oral Antithrombotic Inhibitors: Dabigatran Etexilate, Meeting an Unmet Need?

Clinical and Applied Thrombosis/Hemostasis

Russell Hull¹ 

[1] Thrombosis Research Unit, Foothills Hospital, Calgary, Alberta, [e-mail];

关键词: oral antithrombotic inhibitors;    anticoagulants;    dabigatran;   

DOI  :  10.1177/1076029609344427

来源: Sage Journals

【 摘 要 】

Although effective, vitamin K antagonists (VKAs) are challenging to use because of their slow onset and offset of action, narrow therapeutic window, multiple dietary and drug interactions, and unpredictable anticoagulant effect. Accordingly, it is recognized that there is an unmet need for an oral thrombotic inhibitor that does not require monitoring and has a rapid onset of action. There is also an unmet need in the field of thromboprophylaxis against venous thromboembolism (VTE) in high-risk patients. The topic of this Supplement is the evidence for the use of dabigatran in high-risk orthopedic patients, namely patients with hip and knee athroplasty. An oral therapy with an immediate reliable and predictable anticoagulant effect without the need for coagulation monitoring and without any long-term hepatic or safety concerns will be a major advance in the management of patients with various thrombotic disorders.

【 授权许可】

Unknown   
© 2009 The Author(s)